EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Glycyrrhizinic Acid Derivative YCY ‐20 Inhibits Cerebral Ischemia/Reperfusion Induced Apoptosis via the AGE ‐ RAGE / MAPK Pathway

Jia Luo, Xue Qin, Jiaxin Chen, Xiushi Yu, Ziyun Liu, Jiyi Lv, Xinhui Pan, Yong Chen iD, Lili Wei

CNS Neuroscience & Therapeutics · 2026

DOI: 10.1002/cns.70792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2026. Verfasst von Jia Luo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Ministry of Education, Shihezi University Medical College, Shihezi, China. Hauptthemen laut MEDLINE: Apoptosis, Reperfusion Injury, Neuroprotective Agents, MAP Kinase Signaling System. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Shihezi University Science Foundation of China, the Corps guided science and Technology program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Licorice ( Glycyrrhiza spp.), a traditional Chinese herb, contains glycyrrhetinic acid derivatives with neuroprotective properties but limited bioavailability.

Purpose

YCY‐20 is a novel derivative synthesized by structural modification of 18 β ‐glycyrrhetinic acid. The aim of this study is to explore its therapeutic effect and potential molecular mechanism on cerebral ischemia–reperfusion injury (CIRI).

Methods

Pharmacokinetic profiling was performed to compare plasma exposure and brain distribution of YCY‐20 and its parent compound 18 β ‐GA. Neuroprotection was assessed using middle cerebral artery occlusion/reperfusion (MCAO/R) rats and oxygen–glucose deprivation/reoxygenation (OGD/R)‐induced HT22 cells. Evaluations included infarct volume (TTC staining), apoptosis (TUNEL, flow cytometry), and protein dynamics (Western blot). Network pharmacology identified potential targets, and in vivo experiments are conducted to validate the relevant molecular pathways.

Results

YCY‐20 exhibited improved pharmacokinetic properties, with higher and more stable plasma concentrations and detectable brain levels after oral administration, compared with 18 β ‐GA. YCY‐20 administration significantly attenuated body weight loss, cerebral infarct volume, and neuronal apoptosis in MCAO/R rats. Mechanistically, YCY‐20 suppressed the MCAO/R‐induced upregulation of pro‐apoptotic proteins (Bax, caspase‐3, cleaved caspase‐3) while restoring anti‐apoptotic Bcl‐2 expression. In vitro OGD/R models corroborated these anti‐apoptotic effects. Network analysis identified AGE‐RAGE/MAPK signaling as the predominant pathway modulated by YCY‐20, with subsequent in vivo validation demonstrating its capacity to downregulate key mediators in this pathway.

Conclusions

YCY‐20 confers protection against CIRI, at least partially through apoptosis inhibition mediated by AGE‐RAGE/MAPK signaling pathway modulation. This study provides preclinical evidence for developing licorice‐derived agents in stroke management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApoptosisReperfusion InjuryNeuroprotective AgentsMAP Kinase Signaling SystemGlycyrrhizic AcidGlycyrrhetinic AcidBrain IschemiaAnimalsMaleRatsRats, Sprague-DawleyInfarction, Middle Cerebral ArteryMice

Stichwörter der Autor:innen

AGE‐RAGE/MAPK signaling pathwayYCY‐20apoptosiscerebral ischemia–reperfusion injuryglycyrrhetinic acidnetwork pharmacology

Substanzen

Neuroprotective AgentsGlycyrrhizic AcidGlycyrrhetinic Acid

Autor:innen und Institutionen

  • Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Ministry of Education, Shihezi University Medical College, Shihezi, China.
  • Key Laboratory of Ministry of Education for Xinjiang Phytomedicine Resource and Utilization, School of Pharmacy, Shihezi University, Shihezi, China.
  • Department of Neurology, Peking University Third Hospital, Beijing, China.

ORCID-Profile: Yong Chen

Förderung

  • National Natural Science Foundation of China
  • National Shihezi University Science Foundation of China
  • the Corps guided science and Technology program
  • Peking University Medicine Sailing Program for Young Scholars' Scientific & Technological Innovation

Zitieren

APA

Luo, J., Qin, X., Chen, J., Yu, X., Liu, Z., Lv, J., Pan, X., Chen, Y., & Wei, L. (2026). Novel Glycyrrhizinic Acid Derivative YCY ‐20 Inhibits Cerebral Ischemia/Reperfusion Induced Apoptosis via the AGE ‐ RAGE / MAPK Pathway. CNS Neuroscience & Therapeutics. https://doi.org/10.1002/cns.70792

Vancouver

Luo J, Qin X, Chen J, Yu X, Liu Z, Lv J, et al. Novel Glycyrrhizinic Acid Derivative YCY ‐20 Inhibits Cerebral Ischemia/Reperfusion Induced Apoptosis via the AGE ‐ RAGE / MAPK Pathway. CNS Neuroscience & Therapeutics. 2026. doi:10.1002/cns.70792

BibTeX
@article{Luo2026,
  author = {Luo, Jia and Qin, Xue and Chen, Jiaxin and Yu, Xiushi and Liu, Ziyun and Lv, Jiyi and Pan, Xinhui and Chen, Yong and Wei, Lili},
  title = {Novel Glycyrrhizinic Acid Derivative YCY ‐20 Inhibits Cerebral Ischemia/Reperfusion Induced Apoptosis via the AGE ‐ RAGE / MAPK Pathway},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  doi = {10.1002/cns.70792}
}
Kostenlos starten →